Using Steroids Before Late Preterm Delivery Reduces Neonatal Respiratory Problems
Findings could change clinical care of mothers at risk of late preterm delivery
NEW YORK, NY (February 4, 2016)—A multicenter clinical trial led by researchers at Columbia University Medical Center (CUMC) and NewYork-Presbyterian has found that the use of corticosteroids in mothers at risk for late preterm delivery significantly reduced the incidence of severe respiratory complications in their babies.
“Our study demonstrates that administering a medication that is commonly used to prevent complications in babies born before 34 weeks of gestation can also reduce the risk of many serious complications in babies delivered just a few weeks before term,” said Cynthia Gyamfi-Bannerman, MD, MSc, the Ellen Jacobson Levine and Eugene Jacobson Associate Professor of Women’s Health (in Obstetrics and Gynecology) at CUMC, obstetrician and maternal-fetal medicine specialist at NewYork-Presbyterian and lead investigator of the study. “This will transform the way we care for mothers at risk for late preterm delivery.”
The study was published today in New England Journal of Medicine.
Since the early 1990s, corticosteroids have been widely used in mothers at risk of delivering before 34 weeks of gestation. This treatment accelerates the development of the baby’s lungs, so that once born, the baby is better able to clear fluid and absorb oxygen. At the time, researchers believed that corticosteroids were unnecessary for later preterm births because 99 percent of babies born after 34 to 35 weeks survive. However, it is now clear that infants born during the ‘late’ preterm period (between 34 and 36 weeks) have increased neonatal and childhood respiratory complications compared with newborns born at term (37 weeks or later).
The new study enrolled more than 2,800 pregnant women deemed at high risk of delivery during the late preterm period (34-36 weeks of gestation). The women were randomized to receive two injections of the steroid betamethasone or a placebo, given 24 hours apart.
The study found that babies whose mothers received betamethasone had a significantly lower rate of severe respiratory complications shortly after birth compared with those whose mothers were given a placebo. In particular, neonates from the treatment group had significantly lower rates of bronchopulmonary dysplasia, a lung condition of newborns that increases the risk of chronic lung disease during childhood.
The study also found that babies in the treatment group were significantly less likely to require a long-term stay in the hospital’s neonatal intensive or intermediate care unit or need respiratory treatments such as surfactant.
Approximately 8 percent, or more than 300,000 babies, are born in the late preterm period each year. Of those, roughly 12 percent need persistent respiratory support or have other serious complications requiring prolonged stays in a special care nursery.
“While survival among late preterm infants is comparable to that of babies born at term, the rate of respiratory problems and other serious complications in this group is not comparable and remains unacceptably high,” said Dr. Gyamfi-Bannerman. “Expanding the use of a well-studied, safe medication to improve lung development before birth offers a means of preventing many of these complications.”
Neonates with severe respiratory problems are at higher risk for long-term complications, such as chronic lung disease and neurodevelopmental problems, throughout infancy and childhood. The investigators plan to conduct further studies to determine if giving corticosteroids to mothers at risk for late preterm delivery ameliorates their children’s risk of long-term health problems.
The study is titled Antenatal Late Preterm Steroids (ALPS): a Randomized Trial to Reduce Neonatal Respiratory Morbidity. Authors of the paper include Cynthia Gyamfi-Bannerman, MD, MSc (CUMC); Elizabeth A. Thom, PhD (the George Washington University Biostatistics Center, Washington, DC); Sean C. Blackwell, MD (the University of Texas Health Science Center at Houston–Children’s Memorial Hermann Hospital); Alan T.N. Tita, MD, PhD (University of Alabama at Birmingham, Birmingham); Uma M. Reddy, MD, MPH (the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD); George R. Saade, MD (University of Texas Medical Branch, Galveston); Dwight J. Rouse, MD (Brown University, Providence, RI); David S. McKenna, MD (The Ohio State University, Columbus); Erin A.S. Clark, MD (University of Utah Health Sciences Center, Salt Lake City); John M. Thorp, Jr., MD (University of North Carolina at Chapel Hill); Edward K. Chien, MD, MBA (MetroHealth Medical Center-Case Western Reserve University, Cleveland, OH); Alan M. Peaceman, MD (Northwestern University, Chicago); Ronald S. Gibbs, MD (University of Colorado School of Medicine, Anschutz Medical Campus, Aurora); Geeta K. Swamy, MD (Duke University, Durham, NC); Mary E. Norton, MD (Stanford University, Stanford, CA); Brian M. Casey, MD (University of Texas Southwestern, Dallas); Steve N. Caritis, MD (University of Pittsburgh, Pittsburgh); Jorge E. Tolosa, MD, MSCE (Oregon Health & Sciences University, Portland); Yoram Sorokin, MD (Wayne State University, Detroit); J. Peter VanDorsten, MD (Medical University of South Carolina, Charleston); and Lucky Jain, MD, MBA (Emory University, Atlanta, GA) for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.
Support for the study was provided by the National Heart Lung and Blood Institute (grants HL098554, HL098354); by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grants HD21410, HD27915, HD27917, HD27869, HD34116, HD34208, HD40485, HD40500, HD40512, HD40544, HD40545, HD40560, HD53097, HD53118, HD68268, HD68258, HD68282, HD36801) and by the National Center for Advancing Translational Sciences, National Institutes of Health (UL1 TR000040).
The researchers declare no conflicts of interest.
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.
NewYork-Presbyterian is one of the nation’s most comprehensive healthcare delivery networks, focused on providing innovative and compassionate care to patients in the New York metropolitan area and throughout the globe. In collaboration with two renowned medical school partners, Weill Cornell Medicine and Columbia University College of Physicians & Surgeons, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research and clinical innovation.
NewYork-Presbyterian has four major divisions: NewYork-Presbyterian Hospital is ranked #1 in the New York metropolitan area by U.S. News and World Report and repeatedly named to the magazine’s Honor Roll of best hospitals in the nation; NewYork-Presbyterian Regional Hospital Network is comprised of leading hospitals in and around New York and delivers high-quality care to patients throughout the region; NewYork-Presbyterian Physician Services connects medical experts with patients in their communities; and NewYork-Presbyterian Community and Population Health features the hospital’s ambulatory care network sites and operations, community care initiatives and healthcare quality programs, including NewYork Quality Care, established by NewYork-Presbyterian, Weill Cornell and Columbia.
NewYork-Presbyterian is one of the largest healthcare providers in the U.S. Each year, nearly 29,000 NewYork-Presbyterian professionals deliver exceptional care to more than 2 million patients.
For more information, visit http://nyp.org and find us on Facebook, Twitter and YouTube.